Since SMARCA4 is generally regarded as a tumor suppressor gene and SMARCA4 mutations are thought to be involved in cancer progression, SMARCA2 targeting and the induction of cell death using the concept of synthetic lethality may be considered in the treatment of SMARCA4-mutated cancers. This evidence concerns the gene SMARCA4 and cancer.